REGN2176-3
R2176-3-AMD-1303
Phase 1 small_molecule completed
Quick answer
REGN2176-3 for Neovascular Wet Age-related Macular Degeneration (AMD) is a Phase 1 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- Neovascular Wet Age-related Macular Degeneration (AMD)
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed